Kimco Realty® Management to Present at Nareit’s REITweek: 2026 Investor Conference

Kimco (KIM) reported Q2 2026 FFO per diluted share of $0.46, up 4.5% year over year. Same-property NOI grew 3.5% and occupancy was 96.4%. The company raised full-year FFO guidance to $1.83 to $1.84 per share and same-property NOI guidance to 3.0% to 3.5%, issued $600m exchangeable notes, and declared a $0.28 dividend.

Kimco Realty (NYSE:KIM) reported Q2 FFO of $309.2 million versus $297.6 million a year earlier, with credit loss of 57 bps. The company raised 2026 FFO guidance to $1.83-$1.84 per diluted share, lifted same-property NOI growth to 3%-3.5%, and declared a $0.28 quarterly dividend. Kimco also issued $600 million 3.5% exchangeable notes due 2031 and bought two grocery-anchored centers for $109 million.

Kimco Realty reported record occupancy (92.9% small shop, 96.4% portfolio) and said it launched its “One Kimco” operating model. It raised full-year FFO guidance midpoint and increased the common dividend 12%. The company issued $600m 3.5% exchangeable notes, reported $2.7b liquidity, and projected $33m cash rent from the SNO pipeline in 2026.

Kimco Realty OP, LLC priced an upsized $525 million private placement of 3.50% exchangeable senior notes due June 15, 2031, up from $500 million, with a 13-day option for up to an additional $75 million. Notes mature in 2031 and pay semiannual interest starting Dec. 15, 2026; Kimco guarantees. Initial exchange: 30.9028 shares per $1,000, about a 27.5% premium. Net proceeds: $513.5 million ($587.0 million if option exercised). Kimco plans to use about $104.7 million to repurchase 4.13 million sha

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi